Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases.

In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.

Therapeutics

Pharmaceutical

Life Sciences

Biotechnology

Nitto Avecia

Marie Laliberte

Kristy Bazaire

Derek Julian

Regina Hill

Brian Murphy Mba

Robert Coulter

Andrew Donaldson

Bethany Wood

Jennifer O'Brien

Kenji Nawa

Keri Dufault

Luke Altenau Cpm

Marc Gomez Caminals

Mark Boyle Mba, Cssbb

Steve Trahan

Theresa Vaughan

Natalia Olive

Michael Amend

Cindy Farnsworth

Michelle Leboeuf

Peter Tenaglia

Bob Gallinaro

Taylor Kleineick

Erica B. Blake

The Research and Development team at Nitto Avecia focuses on advancing oligonucleotide technologies to support the creation of innovative therapeutics. Comprising experts in various scientific disciplines, the team conducts cutting-edge research, develops analytical methods, and optimizes processes to ensure the efficient and reliable production of oligonucleotide-based drugs. Their collaborative efforts aim to enhance drug efficacy and contribute to transformative healthcare solutions.

Research and Development

Engineering and Technical Support

Quality Assurance and Compliance

Project Management and Coordination

Research and Development

About

Team members

Other teams at Nitto Avecia

Engineering and Technical Support

Quality Assurance and Compliance

Project Management and Coordination